NCT05237843 is a Phase 1 clinical trial of Hydroxychloroquine in Recurrent Pregnancy Loss, sponsored by Ain Shams University.

Who is sponsoring NCT05237843?

NCT05237843 is sponsored by Ain Shams University.

What drugs are being tested in NCT05237843?

Interventions in NCT05237843: Hydroxychloroquine.

What condition does NCT05237843 study?

NCT05237843 studies Recurrent Pregnancy Loss.

Is NCT05237843 still recruiting?

NCT05237843 is currently status unknown. Last updated 9 February 2022.

Last reviewed 2022-02-09 · How we verify

NCT05237843

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .

Status unknown Phase 1 Last updated 9 February 2022

What this trial tests

Phase 1 trial testing Hydroxychloroquine in Recurrent Pregnancy Loss in 70 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
1 November 2022

1 January 2023

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	70
Start date	1 March 2022
Primary completion	1 November 2022
Estimated completion	1 January 2023

Drugs / interventions tested

Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →

Conditions studied

Recurrent Pregnancy Loss — all drugs for Recurrent Pregnancy Loss →

Sponsor

Ain Shams University

Who can join

Adults 18 to 35, female only, with Recurrent Pregnancy Loss. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To investigate HCQ as a new edition in URPL protocol in change rate of pregnancy loss side by side with anticoagulant traditional treatment
Time frame: one year to be completed
Describing 200 mg of HCQ daily in unexplained recurrent pregnancy loss start once she makes sure of pregnancy till 20 weeks of pregnancy

Sponsor's own description

To investigate efficacy and safety of Hydroxychloroquin in improving pregnancy outcome in women with unexplained recurrent pregnancy loss .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hydroxychloroquine in obstetrics: potential implications of the prophylactic use of hydroxychloroquine for placental insufficiency during pregnancy.
Kim YM, Sung JH, Cha HH, Oh SY. · · 2024 · cited 2× · PMID 38246692 · DOI 10.5468/ogs.23252

Verify or expand the search:

Other trials of Hydroxychloroquine

Trials testing the same drug.

NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06971744 — Autophagy Maintenance (AUTOMAIN) · Phase 2 · recruiting
NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting

Other recruiting trials for Recurrent Pregnancy Loss

Currently open trials in the same condition.

NCT06968026 — Effects of High-Intensity, Low-Frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex on Cardiac Autonomi · NA · recruiting
NCT05725512 — Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages · Phase 4 · recruiting
NCT06182878 — Tender Loving Care for Recurrent Pregnancy Loss · NA · recruiting
NCT05989178 — Prospective Recurrent Pregnancy Loss Registry · recruiting
NCT06007560 — Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss · NA · active not recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05237843 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 9 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05237843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing